Leukemia Clinical Trials & Research
The treatment of lymphoma (Hodgkin’s lymphoma, non-Hodgkin’s lymphomas) is improving every year thanks to discoveries of more effective and safer medicines, long-term and phased (I-IV phases) study of each drug in international clinical trials (trials). A phase I clinical trial in healthy volunteers examines the safety and tolerability of an investigational drug. In subsequent phases, efficacy is determined in patients with lymphoma, the safety and tolerability of experimental therapy are clarified, including its comparison with the officially accepted standards of treatment of the disease.
In practical medicine, the treatment of lymphoma and other diseases is carried out in clinics by the standards approved in the country. These documents are updated every time new medical discoveries appear in the world. Israel, along with many other countries, in full compliance with the approved international standards and national legislation, is actively involved in clinical trials, improving the treatment of lymphoma.
Clinical trials at Tel Aviv Medical Clinic
Our Israeli clinic employs experienced professionals who conduct clinical trials and study the causes of lymphoma. Our department is equipped with modern equipment that helps to study human gene mutations. Clinic staff annually undergo special training and improve their qualifications in international research centres.
There is a need to identify these genetic variations and to tailor treatment options based on the genetic characteristics of the cells. Several multicenter studies are underway around the world in which patients are asked to donate biomaterial samples so that they can be analyzed and saved for future research.
New Drugs and Treatment Regimens
Participation in clinical trials may be the best therapy for some patients with lymphoma. Clinical trials are currently underway to develop treatments that increase the rate of remission or cure disease. The Leukemia and Lymphoma Society continues to invest in research and treatment for the disease. They are also evaluating combinations of chemotherapy drugs with newer targeted therapies. Treatment approaches under investigation include:
- Immunotherapy;
- Phosphoinositide 3-kinase (PI3K) inhibitor;
- Bruton Tyrosine Kinase (BTK) Inhibitor;
- mTOR Inhibitor;
- Other Agents;
- Chimeric antigen receptor (CAR) T-cell therapy;
- Reduced-Intensity Stem Cell Transplantation (Nonmyeloablative Allogeneic Transplantation).